Evidence map›Paper›PMID 40992797›Full record

SynthesisOpen heart2025

Wearable cardioverter defibrillator for transient arrhythmic risk and sudden cardiac death prevention: a systematic review and updated meta-analysis.

Andrea Matteucci, Michela Bonanni, Luca Sgarra, Carlo Pignalberi, Stefano Aquilani, Stefania Angela Di Fusco, Marco Valerio Mariani, Nicola Pierucci, Carlo Lavalle, Silvio Fedele and 2 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrea MatteucciClinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy andrea.matteucci2@gmail.com.ORCID http://orcid.org/0000-0002-8831-6178
Michela BonanniDepartment of Experimental Medicine, University of Rome Tor Vergata, Rome, Lazio, Italy.
Luca SgarraDepartment of Cardiology, Regional General Hospital "F.Miulli', Bari, Italy.
Carlo PignalberiClinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.
Stefano AquilaniClinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.
Stefania Angela Di FuscoClinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.ORCID http://orcid.org/0000-0002-8586-9930
Marco Valerio MarianiDepartment of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, 'Sapienza' University of Rome, Rome, Italy.
Nicola PierucciDepartment of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, 'Sapienza' University of Rome, Rome, Italy.
Carlo LavalleDepartment of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, 'Sapienza' University of Rome, Rome, Italy.
Silvio FedeleDepartment of Interventional Cardiology, Ospedale Sandro Pertini, Rome, Lazio, Italy.
Federico NardiSanto Spirito Hospital, Casale Monferrato, Italy.
Furio ColivicchiClinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSudden cardiac death (SCD) is a common cause of cardiovascular mortality, often triggered by ventricular arrhythmias in the setting of myocardial vulnerability. The wearable cardioverter-defibrillator (WCD) offers temporary protection against SCD, particularly when an implantable device is contraindicated or premature.

objectivesWe conducted a comprehensive meta-analysis to assess the effectiveness of the WCD in appropriately terminating life-threatening arrhythmias such as sustained ventricular tachycardia (VT) and ventricular fibrillation (VF), preventing sudden cardiac death.

methodsFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically reviewed 40 studies comprising 59 647 adults fitted with a WCD for primary or secondary SCD prevention. Random-effects meta-analysis, subgroup analysis, meta-regression and sensitivity analyses were performed.

resultsThe pooled incidence of appropriate WCD intervention was 3% (95% CI 2% to 3%), with substantial heterogeneity (I²=88.9%). The prediction interval ranged from 1% to 8%, indicating that future studies conducted in selected high-risk populations may observe significantly higher WCD intervention. Life-threatening arrhythmias were higher during early follow-up (≤60 days). An appropriate daily WCD wearing time significantly influenced the results. Gender, age, ejection fraction and study design were not significant modifiers. No publication bias was detected.

conclusionsThe WCD represents an effective strategy for preventing SCD in early high-risk settings, with its benefit closely linked to adherence and appropriate patient selection.

Indexed as

Arrhythmias, CardiacDeath, Sudden, CardiacDefibrillatorsElectric CountershockTachycardia, VentricularVentricular FibrillationWearable Electronic DevicesHumansRisk AssessmentRisk FactorsTreatment OutcomeDeath, Sudden, CardiacDefibrillators, ImplantableHealth Care Economics and OrganizationsTachycardia, VentricularVentricular Fibrillation

Identifiers

PMID40992797
PMCPMC12458791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.